0000000000088932

AUTHOR

Peter A. Ringleb

showing 8 related works from this author

Systematic monitoring for detection of atrial fibrillation in patients with acute ischaemic stroke (MonDAFIS): a randomised, open-label, multicentre …

2021

Summary Background Systematic electrocardiogram (ECG) monitoring improves detection of covert atrial fibrillation in stroke survivors but the effect on secondary prevention is unknown. We aimed to assess the effect of systematic ECG monitoring of patients in hospital on the rate of oral anticoagulant use after 12 months. Methods In this investigator-initiated, randomised, open-label, parallel-group multicentre study with masked endpoint adjudication, we recruited patients aged at least 18 years with acute ischaemic stroke or transient ischaemic attack without known atrial fibrillation in 38 certified stroke units in Germany. Patients were randomly assigned (1:1) to usual diagnostic procedur…

Malemedicine.medical_specialtyepidemiology [Atrial Fibrillation]methods [Electrocardiography]Populationdiagnosis [Ischemic Stroke]030204 cardiovascular system & hematologyBrain Ischemia03 medical and health sciencesElectrocardiography0302 clinical medicineRisk FactorsInternal medicineIschaemic strokeAtrial Fibrillationdiagnosis [Brain Ischemia]medicineepidemiology [Brain Ischemia]HumansIn patientMyocardial infarctionddc:610educationepidemiology [Ischemic Stroke]Ischemic StrokeMonitoring PhysiologicAgedAged 80 and overeducation.field_of_studybusiness.industryphysiopathology [Ischemic Stroke]Hazard ratiodiagnosis [Atrial Fibrillation]Atrial fibrillationOdds ratioMiddle Agedmethods [Monitoring Physiologic]medicine.diseasephysiopathology [Atrial Fibrillation]physiopathology [Brain Ischemia]3. Good healthFemaleNeurology (clinical)Open labelbusiness030217 neurology & neurosurgery
researchProduct

Association of prestroke metformin use, stroke severity, and thrombolysis outcome

2020

ObjectiveTo evaluate whether pretreatment with metformin (MET) is associated with less stroke severity and better outcome after IV thrombolysis (IVT), we analyzed a cohort of 1,919 patients with stroke with type 2 diabetes mellitus in a multicenter exploratory analysis.MethodsData from patients with diabetes and ischemic stroke treated with IVT were collected within the European Thrombolysis in Ischemic Stroke Patients (TRISP) collaboration. We applied propensity score matching (PSM) to obtain balanced baseline characteristics of patients treated with and without MET.ResultsOf 1,919 patients with stroke with type 2 diabetes who underwent IVT, 757 (39%) had received MET before stroke (MET+),…

Malemedicine.medical_specialtymedicine.medical_treatment610 Medicine & health030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsModified Rankin ScaleInternal medicineDiabetes mellitusEpidemiologymedicineHumansHypoglycemic AgentsThrombolytic Therapycardiovascular diseases10064 Neuroscience Center ZurichStrokeAgedRetrospective Studiesbusiness.industryRecovery of Function10060 Epidemiology Biostatistics and Prevention Institute (EBPI)ThrombolysisMiddle Agedmedicine.diseaseMetformin10040 Clinic for Neurology3. Good healthMetforminStroke2728 Neurology (clinical)Diabetes Mellitus Type 2Propensity score matchingCohortFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugNeurology
researchProduct

Zeitbasiertes Management des akuten Schlaganfalls

1999

Progression in medical research and economic needs require new planning and organization of treatment strategies. This does also apply for stroke treatment: New pathophysiological knowledge, positive results of thrombolytic therapy and the demostrated importance of early treatment at Stroke Units justify that stroke must be regarded as an emergency. Timing is of utmost importance. Time-based management serves as a planning model for a new stroke treatment strategy. The treatment process is divided into three phases: alarming, pre-hospital and in-hospital phase. The effectiveness of each of these phases is influenced by several variables (personnel, technical equipment, course of the disease…

Information transferbusiness.industryTreatment processDiseaseMedical researchmedicine.diseasePhase (combat)Stroke treatmentEmergency MedicineMedicineMedical emergencybusinessPublic educationStrokeNotfall & Rettungsmedizin
researchProduct

Intravenous thrombolysis for suspected ischemic stroke with seizure at onset

2019

Objective Seizure at onset (SaO) has been considered a relative contraindication for intravenous thrombolysis (IVT) in patients with acute ischemic stroke, although this appraisal is not evidence based. Here, we investigated the prognostic significance of SaO in patients treated with IVT for suspected ischemic stroke. Methods In this multicenter, IVT-registry-based study we assessed the association between SaO and symptomatic intracranial hemorrhage (sICH, European Cooperative Acute Stroke Study II definition), 3-month mortality, and 3-month functional outcome on the modified Rankin Scale (mRS) using unadjusted and adjusted logistic regression, coarsened exact matching, and inverse probabil…

0301 basic medicineMalemedicine.medical_specialtymedicine.medical_treatmentLogistic regressionGUIDELINESCLASSIFICATION3124 Neurology and psychiatryBrain IschemiaEARLY MANAGEMENT03 medical and health sciences0302 clinical medicineALTEPLASEModified Rankin ScaleSeizuresMIMICSInternal medicineMedicineHumansThrombolytic TherapyPLASMINOGEN-ACTIVATOR610 Medicine & healthStrokeContraindicationPOPULATIONAgedAged 80 and overHEALTH-CARE PROFESSIONALSbusiness.industryConfounding3112 NeurosciencesOdds ratioThrombolysisASSOCIATIONMiddle Agedmedicine.diseasePrognosisConfidence intervalStroke030104 developmental biologyTreatment OutcomeNeurologySAFETYFemaleNeurology (clinical)business030217 neurology & neurosurgery
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany - A national case collection.

2017

BackgroundIdarucizumab is a monoclonal antibody fragment with high affinity for dabigatran that reverses its anticoagulant effects within minutes. It may exhibit the potential for patients under dabigatran therapy suffering ischemic stroke to regain eligibility for thrombolysis with rt-PA and may inhibit lesion growth in patients with intracerebral hemorrhage on dabigatran.AimsTo provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of ischemic stroke or intracranial hemorrhage.MethodsRetrospective data collected from German neurological/neurosurgical departments administering idarucizumab following product launch…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizin030204 cardiovascular system & hematologyAntibodies Monoclonal HumanizedAntithrombinsDabigatranBrain Ischemia03 medical and health sciences0302 clinical medicineHematomaGermanymedicineHumansThrombolytic TherapyStrokeAgedRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabThrombolysismedicine.diseaseSurgeryDabigatranStrokeNeurologyAnesthesiaTissue Plasminogen ActivatorFemalebusinessIntracranial Hemorrhages030217 neurology & neurosurgerymedicine.drugInternational journal of stroke : official journal of the International Stroke Society
researchProduct

Antagonizing dabigatran by idarucizumab in cases of ischemic stroke or intracranial hemorrhage in Germany—Updated series of 120 cases

2020

Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for thrombolysis with recombinant tissue-type plasminogen activator (rt-PA). In patients on dabigatran with intracerebral hemorrhage idarucizumab could prevent lesion growth. Aims To provide insights into the clinical use of idarucizumab in patients under effective dabigatran anticoagulation presenting with signs of acute ischemic stroke or intracranial hemorrhage. Methods Retrospective data collected from German neurological/neurosurgical departments ad…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentMedizinAntibodies Monoclonal HumanizedAntithrombinsBrain IschemiaDabigatranGermanyInternal medicinemedicineHumansThrombolytic Therapyddc:610Ischemic StrokeRetrospective StudiesIntracerebral hemorrhagebusiness.industryAnticoagulantWarfarinIdarucizumabAtrial fibrillationThrombolysisVitamin K antagonistmedicine.diseaseDabigatranStrokeNeurologyCardiologybusinessIntracranial Hemorrhagesmedicine.drugInternational Journal of Stroke
researchProduct

Renal Impairment Is Associated with Intracerebral Hemorrhage after Mechanical Thrombectomy in Vertebrobasilar Stroke

2018

<b><i>Background and Purpose:</i></b> Renal dysfunction (RD) is overall associated with unfavorable functional outcome and higher risk of mortality after acute ischemic stroke. Associations between RD and outcome in patients with acute vertebrobasilar stroke treated with thrombectomy have not been evaluated so far. <b><i>Materials and Methods:</i></b> Consecutive patients with vertebrobasilar stroke treated with mechanical thrombectomy between October 2010 and July 2017 at our center were analyzed. RD was defined as glomerular filtration rate (GFR) < 60 mL/min/1.73 m<sup>2</sup> at admission. Endpoints were (I) poor clinic…

Malemedicine.medical_specialtyTime FactorsDatabases FactualStroke severityRenal function030204 cardiovascular system & hematologyKidneyRisk Assessment03 medical and health sciences0302 clinical medicineRisk FactorsVertebrobasilar strokeInterquartile rangeInternal medicineVertebrobasilar InsufficiencyRisk of mortalitymedicineHumansIn patientcardiovascular diseasesAgedCerebral HemorrhageThrombectomyAged 80 and overIntracerebral hemorrhagebusiness.industryMiddle Agedmedicine.diseaseStrokeMechanical thrombectomyTreatment OutcomeNeurologyCardiologyFemaleKidney DiseasesNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryGlomerular Filtration RateCerebrovascular Diseases
researchProduct

Non-office-hours admission affects intravenous thrombolysis treatment times and clinical outcome

2018

In patients treated with intravenous thrombolysis (IVT), an unfavourable ‘non-office-hours effect’ on door-to-needle time (DNT) and clinical outcome has been suggested. This effect has been attributed to a number of factors, mostly related to either less efficient logistics or less (experienced) staffing during non-office hours (NH). These factors could result in longer DNTs and more protocol violations and thus in worse clinical outcome. On the other hand, one could also argue that the workload during NH is lower, which could result in less time delays in the various diagnostic processes and thus in better clinical outcome. Our hypothesis is that admission during NH has a negative effect o…

MaleTime delaysmedicine.medical_specialtyTime Factorsmedicine.medical_treatmentOutcome (game theory)Time-to-TreatmentCohort Studies03 medical and health sciences0302 clinical medicinePatient AdmissionModified Rankin ScaleIschaemic strokemedicineHumansThrombolytic Therapy030212 general & internal medicineStrokeAgedAged 80 and overbusiness.industryThrombolysisMiddle Agedmedicine.diseasestroke3. Good healthMechanical thrombectomyPsychiatry and Mental healthTreatment OutcomeEmergency medicineCohortPhysical therapySurgeryFemaleNeurology (clinical)business030217 neurology & neurosurgeryJournal of neurology, neurosurgery, and psychiatry
researchProduct